Cargando…

Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials

Alemtuzumab (ALEM) is widely used as an induction therapy for organ transplantation, and numerous randomized controlled trials (RCTs) have been published to evaluate its efficacy and safety in kidney transplantation as compared with antithymocyte globulin (ATG). The purpose of this study was to comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jianming, Song, Wenli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515737/
https://www.ncbi.nlm.nih.gov/pubmed/28700465
http://dx.doi.org/10.1097/MD.0000000000007151

Ejemplares similares